CAJ | 학술논문

小细胞肺癌（SCLC）靶向治疗药物包括血管生成抑制剂、酪氨酸激酶抑制剂和信号通路抑制剂等。研究表明血管生成抑制剂如贝伐珠单抗疗效并不显著；酪氨酸激酶抑制剂如舒尼替尼等可能更适合单药治疗；信号通路抑制剂如 Amuvatinib、LDE225等正在进行Ⅰ、Ⅱ期临床试验。目前认为 SCLC对于靶向治疗不敏感，或更具有选择性和针对性，有待于进一步研究。
소세포폐암（SCLC）파향치료약물포괄혈관생성억제제、락안산격매억제제화신호통로억제제등。연구표명혈관생성억제제여패벌주단항료효병불현저；락안산격매억제제여서니체니등가능경괄합단약치료；신호통로억제제여 Amuvatinib、LDE225등정재진행Ⅰ、Ⅱ기림상시험。목전인위 SCLC대우파향치료불민감，혹경구유선택성화침대성，유대우진일보연구。
Targeted agents for small cell lung cancer (SCLC)include inhibitors of angiogenesis,tyro-sine kinase inhibitors and signal transduction pathway inhibitors.Bevacizumab,a class of antiangiogenic agent, tends to have no effects on patients.The tyrosine kinase inhibitor,for example sunitinib,may be used as a monotherapy.Signaling inhibitors including Amuvatinib and LDE225 are undergoing phaseⅠand Ⅱ trials.Pri-mary data show that SCLC is not sensitive to targeted therapy,needing more selection,so further studies are requested.